Table 4.
Pathologic complete response according to breast cancer subtype in four Alliance clinical trials
| ER+/HER2− (N=416) | ER+/HER2+ (N=406) | ER−/HER2+ (N=313) | Triple Negative (N=648) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | % pCR | OR (95% CI)a | N | % pCR | OR (95% CI)a | N | % pCR | OR (95% CI)a | N | % pCR | OR (95% CI)a | |
| Race | ||||||||||||
| White | 343 | 51 (14.9) | 1.0 (reference) | 323 | 125 (38.7) | 1.0 (reference) | 254 | 156 (61.4) | 1.0 (reference) | 450 | 211 (46.9) | 1.0 (reference) |
| Black | 52 | 9 (17.3) | 1.04 (0.41, 2.66) | 42 | 18 (42.9) | 1.42 (0.66, 3.08) | 30 | 18 (60.0) | 0.65 (0.27, 1.59) | 121 | 54 (44.6) | 1.09 (0.70, 1.72) |
| Ethnicity | ||||||||||||
| Non-Hispanic | 361 | 53 (14.7) | 1.0 (reference) | 307 | 120 (39.1) | 1.0 (reference) | 250 | 153 (61.2) | 1.0 (reference) | 513 | 238 (46.4) | 1.0 (reference) |
| Hispanic | 38 | 7 (18.4) | 1.24 (0.45, 3.38) | 59 | 26 (44.1) | 1.30 (0.67, 2.53) | 49 | 32 (65.3) | 0.97 (0.47, 2.03) | 47 | 24 (51.1) | 1.32, (0.68, 2.54) |
| BMI (kg/m2) | ||||||||||||
| <20 | 12 | 3 (25.0) | 1.75 (0.32, 9.52) | 19 | 9 (47.4) | 1.03 (0.34, 3.13) | 12 | 10 (83.3) | 4.49 (0.84, 24.1) | 21 | 11 (52.4) | 1.32 (0.50, 3.48) |
| 20–24 | 104 | 18 (17.3) | 1.0 (reference) | 109 | 52 (47.7) | 1.0 (reference) | 90 | 49 (54.4) | 1.0 (reference) | 145 | 74 (51.0) | 1.0 (reference) |
| 25–29 | 124 | 20 (16.1) | 1.27 (0.54, 2.98) | 116 | 30 (25.9) | 0.36 (0.19, 0.67) | 87 | 62 (71.3) | 2.24 (1.09, 4.62) | 178 | 83 (46.6) | 0.81, (0.50, 1.31) |
| ≥30 | 176 | 25 (14.2) | 0.97 (0.43, 2.18) | 155 | 61 (39.4) | 0.68 (0.38, 1.22) | 122 | 74 (60.7) | 1.35 (0.72, 2.54) | 267 | 117 (43.8) | 0.72 (0.46, 1.14) |
| p-trend b | 0.88 | 0.010 | 0.082 | 0.40 | ||||||||
a
mutually adjusted for all variables in table plus trial arm, tumor grade, and lymph node status
b
p-trend is from a test for linear trend of an ordinal variable defined by the median of each category